Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells

被引:63
作者
Chekhun, VF
Kulik, GI
Yurchenko, OV
Tryndyak, VP
Todor, IN
Luniv, LS
Tregubova, NA
Pryzimirska, TV
Montgomery, B
Rusetskaya, NV
Pogribny, IP [1 ]
机构
[1] Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA
[2] RE Kavetsky Inst Expt Pathol Oncol & Radiobiol, Dept Mech Anticanc Therapt, Kiev, Ukraine
关键词
MCF-7; cells; doxorubicin resistance; DNA hypomethylation;
D O I
10.1016/j.canlet.2005.01.038
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The resistance of cancer cells to chemotherapeutic agents is a major clinical problem and an important cause of treatment failure in cancer. Mechanisms that have developed to guard cancer cells against anti-cancer drugs are major barriers to successful anti-cancer therapy. Therefore, the identification of novel mechanisms of cellular resistance holds the promise of leading to better treatments for cancer patients. In the present study, we used human MCF-7 breast adenocarcinoma cell line and its doxorubicin-resistant variant MCF-7/R to determine the role of alterations of DNA methylation of chemoresitance-related genes, such as multidrug resistance 1 (MDR1), glutathione-S-transferase (GST pi), O-6-methylguanine DNA methyltransferase (MGMT), and urokinase (Upa), in the development of drug resistance. The promoter regions of MDR1, GST pi, MGMT, and Upa genes were highly methylated in MCF-7 cell line but not in its MCF-7/R drug resistant variant. The hypomethylated status of MDR1 gene was associated with overexpression of P-glycoprotein. We hypothesize that acquirement of doxorubicin resistance of MCF-7 cells is associated with DNA hypomethylation of the promoter regions of the MDR1, GST pi, MGMT, and Upa genes. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 23 条
[1]   P-glycoprotein: from genomics to mechanism [J].
Ambudkar, SV ;
Kimchi-Sarfaty, C ;
Sauna, ZE ;
Gottesman, MM .
ONCOGENE, 2003, 22 (47) :7468-7485
[2]  
CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
[3]   MDR1 promoter hypermethylation in MCF7 human breast cancer cells - Changes in chromatin structure induced by treatment with 5-aza-cytidine [J].
David, GL ;
Yegnasubramanian, S ;
Kumar, A ;
Marchi, VL ;
De Marzo, AM ;
Lin, XH ;
Nelson, WG .
CANCER BIOLOGY & THERAPY, 2004, 3 (06) :540-548
[4]   Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation [J].
El-Osta, A ;
Kantharidis, P ;
Zalcberg, JR ;
Wolffe, AP .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (06) :1844-1857
[5]   CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer [J].
Enokida, H ;
Shiina, H ;
Igawa, M ;
Ogishima, T ;
Kawakami, T ;
Bassett, WW ;
Anast, JW ;
Li, LC ;
Urakami, S ;
Terashima, M ;
Verma, M ;
Kawahara, M ;
Nakagawa, M ;
Kane, CJ ;
Carroll, PR ;
Dahiya, R .
CANCER RESEARCH, 2004, 64 (17) :5956-5962
[6]   Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant [J].
Faute, MAD ;
Laurent, L ;
Ploton, D ;
Poupon, MF ;
Jardillier, JC ;
Bobichon, H .
CLINICAL & EXPERIMENTAL METASTASIS, 2002, 19 (02) :161-168
[7]   Mechanisms of cancer drug resistance [J].
Gottesman, MM .
ANNUAL REVIEW OF MEDICINE, 2002, 53 :615-627
[8]   A novel DNA damage checkpoint involving post-transcriptional regulation of cyclin A expression [J].
Guo, N ;
Faller, DV ;
Vaziri, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (03) :1715-1722
[9]  
Harada Taishi, 2000, International Journal of Cancer, V86, P506, DOI 10.1002/(SICI)1097-0215(20000515)86:4<506::AID-IJC10>3.0.CO
[10]  
2-8